News | April 06, 2022
AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain
The new facility is scheduled to start operation in the first half of 2024
The new facility is scheduled to start operation in the first half of 2024
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Expected to open later this year, the facility will significantly increase distribution capacity to meet the growing demand for production materials by Ireland's biopharma industry
The company has operations in North America, Asia, and Europe,
The platform revolutionizes how providers deliver financial services by radically simplifying the patient financial experience
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
